GP-Act III Acquisition Common Stock

The latest common stock for GPAT is $200M as of June 2026. That compares with $300M in the prior-year period — down 35.1% year over year. Investors often review this figure alongside GP-Act III Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, GPAT's common stock moved from $300M to $200M — a 35.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GP-Act III Acquisition's operating scale or balance-sheet position.

A common stock figure of $200M for GPAT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GPAT's common stock ($200M), review year-over-year change from $300M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.